# Mytesi® (crofelemer) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/crofelemer

> The FDA approved Mytesi® (crofelemer), sponsored by Jaguar Health, Inc. (JAGX), on April 12, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Mytesi® (crofelemer) FDA approved?

Yes. The FDA approved Mytesi® (crofelemer), sponsored by Jaguar Health, Inc. (JAGX), on April 12, 2024. SEC Form 10-Q: "As part of our strategy to expand our commercial footprint beyond the FDA approved crofelemer indication for HIV-related supportive care, to include cancer-related supportive care, on April 12, 2024, we entered into an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC ("Venture Life"), an international consumer health company focused on the global self-care market, for Venture Life's 510(k) cleared oral mucositis prescription product, Gelclair, for the US market." [Calendar and source filings](https://sec-api.dev/pdufa/crofelemer)

Source: SEC Form 10-Q, accession 0001193125-25-282950, https://www.sec.gov/Archives/edgar/data/1585608/000119312525282950/jagx-20250930.htm (retrieved 2026-11-12). Last confirmed 2025-11-14. Cite: https://sec-api.dev/pdufa/crofelemer#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Mytesi® (crofelemer) |
| Codes |  |
| Sponsor | Jaguar Health, Inc. (JAGX) https://sec-api.dev/companies/jagx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | breakthrough, orphan |

## Timeline

### April 12, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-11-14, last confirmed 2025-11-14.
- SEC Form 10-Q (accession 0001193125-25-282950): "As part of our strategy to expand our commercial footprint beyond the FDA approved crofelemer indication for HIV-related supportive care, to include cancer-related supportive care, on April 12, 2024, we entered into an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC ("Venture Life"), an international consumer health company focused on the global self-care market, for Venture Life's 510(k) cleared oral mucositis prescription product, Gelclair, for the US market." https://www.sec.gov/Archives/edgar/data/1585608/000119312525282950/jagx-20250930.htm

### Jul 2024: topline data readout

- Status: completed, missed. Date confidence: month.
- First seen 2026-11-09, last confirmed 2026-11-09.
- SEC prospectus (424B) (accession 0001193125-26-452741): "As announced in July of 2024, the top line results from the OnTarget study showed that the trial did not meet its primary endpoint for the prespecified analysis of all tumor types and all targeted therapies." https://www.sec.gov/Archives/edgar/data/1585608/000119312526452741/d169732d424b5.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/crofelemer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mytesi® (crofelemer) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/crofelemer

```bibtex
@misc{secapidev_pdufa_crofelemer_20261116,
  title        = {Mytesi® (crofelemer) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/crofelemer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_crofelemer_20261116","title":"Mytesi® (crofelemer) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/crofelemer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
